Dónal Landers is Clinical Leader for the iDecide programme at The Cancer Research UK Manchester Institute, a world-leading centre for excellence in cancer research. Dónal obtained his primary medical degree from Trinity College, Dublin. He has an MBA from University College Dublin, and studied Computer Science at Dublin City University. He has a certificate in Translational Medicine from the University of Manchester and is a Member of the Faculty of Pharmaceutical Medicine where he has completed his higher medical training in this specialty. He is a Senior Director Physician with AstraZeneca and leads a large global study, primarily in bladder cancer in Early Clinical Development (ECD) combining immune checkpoint inhibitors and targeted therapies.